Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA

Growdon Whitfield; Hernandez Silvia F.; Chisholm Sarah; Borger Darrell; Foster Rosemary; Rueda Bo R.

首页> 外文期刊>Gynecologic Oncology: An International Journal >Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA

【24h】

Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA

机译：Ridaforolimus通过HER2基因扩增和在PIK3CA中获得功能突变来改善子宫浆液性癌体内模型中双重HER2双重阻断的抗肿瘤活性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Gynecologic Oncology: An International Journal》 |2015年第3期|共1页
作者
Growdon Whitfield; Hernandez Silvia F.; Chisholm Sarah; Borger Darrell; Foster Rosemary; Rueda Bo R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA [J] . Growdon Whitfield, Hernandez Silvia F., Chisholm Sarah, Gynecologic Oncology: An International Journal . 2015,第3期

机译：Ridaforolimus通过HER2基因扩增和在PIK3CA中获得功能突变来改善子宫浆液性癌体内模型中双重HER2双重阻断的抗肿瘤活性
2. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo [J] . Lopez Salvatore, Cocco Emiliano, Black Jonathan, Molecular cancer therapeutics . 2015,第11期

机译：双HER2 / PIK3CA靶向克服了在体外和体内HER2扩增的子宫浆液癌细胞系中的单药剂的抗性
3. Oncogenic PIK3CA gene mutations and HER2eu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class i PI3 kinase and mTOR kinase (TORC1/2) [J] . American Journal of Obstetrics and Gynecology . 2013,第5期

机译：致癌的PIK3CA基因突变和HER2 / neu基因扩增决定了子宫浆液性癌细胞系对GDC-0980的敏感性，GDC-0980是i类PI3激酶和mTOR激酶（TORC1 / 2）的选择性抑制剂
4. Dual HER2PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo [O] . Salvatore Lopez, Emiliano Cocco, Jonathan Black, -1

机译：双重靶向HER2 PIK3CA靶向在体外和体内克服了HER2扩增的子宫浆液性癌细胞系中的单药获得性耐药
5. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo [O] . Salvatore Lopez, Carlton L. Schwab, Emiliano Cocco, 2014

机译：Taselisib是一种Pik3Ca的选择性抑制剂，在Pik3CA突变和HER2 / Neu扩增的子宫浆液癌体外高度有效，体内和体内

Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA

著录项

相似文献

相关主题

期刊订阅